Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 2 The 4-Year Follow-Up of Randomized Trials of SES Versus BMS and PES Versus BMS
At 4 years of follow-up, there is a slight but nonsignificant difference in mortality for both sirolimus-eluting stents (SES) (A) and paclitaxel-eluting stents (PES) (B) versus bare-metal stents (BMS) but no difference in myocardial infarction. The beneficial effect of both drug-eluting stents in reducing procedures for restenosis (target lesion revascularization) remain. Used with permission from Stone et al. (13).
|
